Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product
MWN-AI** Summary
Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) is advancing its lead product, HemaXellerate, an innovative stem cell-derived therapy that has received FDA Investigational New Drug clearance. The company aims primarily to treat aplastic anemia, a rare disorder characterized by the bone marrow's inability to produce sufficient blood cells, yet is also exploring broader applications, including chemotherapy-induced bone marrow suppression.
David Koos, Chairman and CEO of Regen BioPharma, announced plans to seek Orphan Drug Designation for HemaXellerate. This designation could provide critical advantages, such as a 25% tax credit on qualified clinical testing expenses and up to seven years of marketing exclusivity. The potential incentives underscore the company’s commitment to addressing high unmet medical needs in rare diseases.
HemaXellerate utilizes adipose-derived cells processed through a proprietary method aimed at stimulating bone marrow regeneration damaged by autoimmune conditions or therapies like chemotherapy and radiation. With the treatment landscape for aplastic anemia limited, HemaXellerate could redefine patient care, especially for those lacking access to bone marrow transplants.
Regen BioPharma's strategic collaboration with a leading clinical research organization ensures that the forthcoming Phase 1 trial will be executed efficiently, with an expected completion timeline of 12 to 14 months. The company’s focus on HemaXellerate could not only fulfill a significant market need but may also open doors to a multi-billion-dollar sector in treating chemotherapy-induced bone marrow suppression.
In summary, Regen BioPharma's innovative approach and commitment to developing therapies for hematological disorders position the company for potential growth in a promising market, making it an intriguing prospect for investors. More information can be found on their website at [Regen BioPharma](http://www.regenbiopharmainc.com).
MWN-AI** Analysis
Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) presents an intriguing investment opportunity in the burgeoning biotech sector, particularly with the anticipated Phase 1 clinical trial for its proprietary therapy, HemaXellerate. This innovative approach to treating aplastic anemia, which has received FDA clearance, could set the stage for Regen BioPharma to capitalize on significant incentives by pursuing Orphan Drug Designation.
The pursuit of this designation is strategic, as it offers a 25% tax credit on qualified clinical expenses and up to seven years of marketing exclusivity. These benefits could significantly lower operational costs and enhance market positioning, especially for a therapy directed at a rare and underserved patient population.
Moreover, the expansion of HemaXellerate's application to treat chemotherapy-induced bone marrow suppression represents a lucrative opportunity. The market for this condition alone is projected to exceed $1 billion annually, emphasizing the potential for robust revenue streams beyond the initial target area.
Regen BioPharma's collaboration with a reputable clinical research organization (CRO) adds credibility and strengthens its execution strategy for the trial's success. By ensuring adherence to timelines and regulatory standards, this partnership could enable the company to effectively navigate the complex phases of clinical development.
For investors, Regen BioPharma offers a dual opportunity: engagement in a potentially groundbreaking treatment for aplastic anemia and broader hematological disorders, alongside access to incentives that can catalyze growth. However, it is crucial to keep in mind the inherent risks involved in biotechnology investments, including regulatory hurdles and market competition.
In summary, Regen BioPharma's strategic direction and innovative therapies may provide compelling investment potential, particularly if they successfully achieve Orphan Drug status and capitalize on the expanding market for hematological treatments. As always, thorough due diligence is advisable before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
An Orphan Drug Designation Could Provide Significant Benefits to Regen
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provides further insight into its planned Phase 1 clinical trial of HemaXellerate , the company’s innovative stem cell-derived therapy, which has already received FDA Investigational New Drug Application (IND) clearance. While the initial focus is on treating aplastic anemia, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in a market poised for significant growth.
David Koos, the Chairman and CEO of Regen Biopharma, Inc., discussed the Company’s intention to seek Orphan Drug Designation for HemaXellerate, the Company’s proprietary aplastic anemia cell therapy drug candidate. This designation supports the development of medicines for rare disorders
“The incentives gained by being granted Orphan Drug designation would be substantial,” stated Koos. “These incentives include a tax credit equal to 25% of qualified clinical testing expenses (QCTEs) as well as up to seven years of marketing exclusivity. Regen intends to vigorously pursue Orphan Drug designation for HemaXellerate.”
The Company has been granted clearance by the United States FDA to initiate a Phase I clinical trial for HemaXellerate. HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells.
HemaXellerate ™ is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. While the company’s initial target is aplastic anemiait sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market valued at over $1 billion annually.
“ Aplastic anemia patients without access to bone marrow transplantation face limited options,” said Dr. David Koos. , “With FDA clearance to begin clinical trials, HemaXellerate ™ has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.”
To ensure the trial’s success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months.
Key Highlights for Investors:
- Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity.
- Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market.
- Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence.
About Regen BioPharma, Inc.
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com .
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharmainc.com or
david.koos@regenbiopharma.com
X (formerly twitter): https: //x.com/TheRegenBio
FAQ**
How does Regen BioPharma Inc plan to leverage the potential Orphan Drug Designation for HemaXellerate in terms of regulatory advantages and funding opportunities, particularly with "Regen Biopharma Inc PRF PERPETUAL USD - Ser A RGBPP"?
What specific milestones does Regen BioPharma intend to achieve during the Phase 1 clinical trial of HemaXellerate that could impact investor confidence in "Regen Biopharma Inc PRF PERPETUAL USD - Ser A RGBPP"?
How will Regen BioPharma's partnership with a clinical research organization enhance the trial's execution timeline and success rate, especially in relation to "Regen Biopharma Inc PRF PERPETUAL USD - Ser A RGBPP"?
Given the potential market expansion into chemotherapy-induced bone marrow suppression, what strategies does Regen BioPharma have in place to differentiate HemaXellerate from existing therapies, while discussing "Regen Biopharma Inc PRF PERPETUAL USD - Ser A RGBPP"?
**MWN-AI FAQ is based on asking OpenAI questions about Regen BioPharma Inc (OTC: RGBP).
NASDAQ: RGBP
RGBP Trading
-25.0% G/L:
$0.0009 Last:
6,510,034 Volume:
$0.001 Open:
